Kiniksa Highlights Corporate Priorities and Expected 2021 Milestones
January 11, 2021 08:00 ET
|
Kiniksa Pharmaceuticals, Ltd.
- PDUFA goal date of March 21, 2021 for rilonacept in recurrent pericarditis -- Data from Phase 2 portion of mavrilimumab Phase 2/3 trial in severe COVID-19 pneumonia and hyperinflammation expected in...
Kiniksa Pharmaceuticals to Present at 39th Annual J.P. Morgan Healthcare Conference
January 04, 2021 16:20 ET
|
Kiniksa Pharmaceuticals, Ltd.
HAMILTON, Bermuda, Jan. 04, 2021 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) announced today that it will present at the 39th Annual J.P. Morgan Healthcare Conference on Monday,...
Kiniksa Announces Data from U.S. Investigator-Initiated Study of Mavrilimumab in Severe COVID-19 Pneumonia and Hyperinflammation
December 22, 2020 08:00 ET
|
Kiniksa Pharmaceuticals, Ltd.
- Early signal of efficacy with trends toward lower mortality and shorter duration of mechanical ventilation in patients treated with mavrilimumab – - Data from the Phase 2 portion of Kiniksa’s...
Kiniksa Commences Dosing of Vixarelimab Phase 2b Clinical Trial in Prurigo Nodularis
December 15, 2020 08:00 ET
|
Kiniksa Pharmaceuticals, Ltd.
HAMILTON, Bermuda, Dec. 15, 2020 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) (“Kiniksa”), a biopharmaceutical company with a pipeline of assets designed to modulate...
Kiniksa Announces Preliminary Data from Phase 1 Trial of KPL-404
November 30, 2020 08:00 ET
|
Kiniksa Pharmaceuticals, Ltd.
- Receptor occupancy and TDAR suppression shown through Day 29 at 3 mg/kg intravenous – - Data to-date support subsequent study in patients, including potential intravenous or subcutaneous monthly...
Kiniksa Pharmaceuticals to Present at the Evercore ISI 3rd Annual HealthCONx Conference
November 24, 2020 08:00 ET
|
Kiniksa Pharmaceuticals, Ltd.
HAMILTON, Bermuda, Nov. 24, 2020 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) announced today that it will present at the Evercore ISI 3rd Annual HealthCONx Conference on...
Kiniksa Announces U.S. FDA Acceptance of sBLA and Priority Review for Rilonacept in Recurrent Pericarditis
November 23, 2020 08:00 ET
|
Kiniksa Pharmaceuticals, Ltd.
- PDUFA goal date of March 21, 2021 -- Filing based on positive data from RHAPSODY, which achieved its primary and all major secondary endpoints -- Rilonacept BLA for CAPS transferred to Kiniksa from...
Kiniksa Announces New England Journal of Medicine Publication of Rilonacept Phase 3 Data in Recurrent Pericarditis and Late-Breaking Science Presentation at American Heart Association Scientific Sessions 2020
November 17, 2020 08:00 ET
|
Kiniksa Pharmaceuticals, Ltd.
HAMILTON, Bermuda, Nov. 17, 2020 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) (“Kiniksa”), a biopharmaceutical company with a pipeline of assets designed to modulate...
Kiniksa Announces Breakthrough Therapy Designation Granted to Vixarelimab for the Treatment of Pruritus Associated with Prurigo Nodularis
November 16, 2020 08:00 ET
|
Kiniksa Pharmaceuticals, Ltd.
HAMILTON, Bermuda, Nov. 16, 2020 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) (“Kiniksa”), a biopharmaceutical company with a pipeline of assets designed to modulate...
Kiniksa Announces American College of Rheumatology Convergence 2020 Late-Breaking Abstracts Presentation of Mavrilimumab Phase 2 Giant Cell Arteritis Data
November 09, 2020 16:01 ET
|
Kiniksa Pharmaceuticals, Ltd.
HAMILTON, Bermuda, Nov. 09, 2020 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) (“Kiniksa”), a biopharmaceutical company with a pipeline of assets designed to modulate...